Senator Collins' Statement on FDA Decision to Grant Full Approval of Alzheimer's Drug
July 08, 2023
July 08, 2023
WASHINGTON, July 8 -- Sen. Susan M. Collins, R-Maine, issued the following statement on July 6, 2023:
* * *
Today, U.S. Senator Susan Collins (R-ME), the chairman and founder of the Senate Alzheimer's Task Force, expressed support for the U.S. Food and Drug Administration's (FDA) decision to grant full approval of the Alzheimer's drug, Leqembi:
"FDA's approval of Leqembi is a new milestone in the treatment of Alzheimer's diseas . . .
* * *
Today, U.S. Senator Susan Collins (R-ME), the chairman and founder of the Senate Alzheimer's Task Force, expressed support for the U.S. Food and Drug Administration's (FDA) decision to grant full approval of the Alzheimer's drug, Leqembi:
"FDA's approval of Leqembi is a new milestone in the treatment of Alzheimer's diseas . . .